These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 38514793)
1. Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models. Jamali A; Ho N; Braun A; Adabi E; Thalheimer FB; Buchholz CJ EMBO Mol Med; 2024 Apr; 16(4):784-804. PubMed ID: 38514793 [TBL] [Abstract][Full Text] [Related]
2. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model]. Shan JQ; Nan SF; Li F; Shen CY; Zhang Y Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632 [No Abstract] [Full Text] [Related]
3. IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro. Zhang H; Lv X; Kong Q; Tan Y Hum Vaccin Immunother; 2022 Dec; 18(1):1-14. PubMed ID: 35049413 [TBL] [Abstract][Full Text] [Related]
4. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M Front Immunol; 2021; 12():745320. PubMed ID: 34712233 [TBL] [Abstract][Full Text] [Related]
5. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy. Read JA; Rouce RH; Mo F; Mamonkin M; King KY Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718 [TBL] [Abstract][Full Text] [Related]
6. The Qi Yin San Liang San decoction enhances anti-CD19 CAR-T cell function in the treatment of B-cell lymphomas. Dong S; Wang P; Zhang L; Zhang X; Li X; Wang J; Cui X; Lan T; Gao C; Shi Y; Wang W; Wang J; Jiang M J Ethnopharmacol; 2024 Jan; 319(Pt 1):117109. PubMed ID: 37657771 [TBL] [Abstract][Full Text] [Related]
7. Cell-Based Models of 'Cytokine Release Syndrome' Endorse CD40L and Granulocyte-Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy. Dibas A; Rhiel M; Patel VB; Andrieux G; Boerries M; Cornu TI; Alzubi J; Cathomen T Cells; 2023 Nov; 12(21):. PubMed ID: 37947658 [TBL] [Abstract][Full Text] [Related]
8. Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy. Zhang Y; Zhuang Q; Wang F; Zhang C; Xu C; Gu A; Zhong WH; Hu Y; Zhong X J Transl Med; 2022 Sep; 20(1):432. PubMed ID: 36167591 [TBL] [Abstract][Full Text] [Related]
9. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies. Dos Santos DMC; Rejeski K; Winkelmann M; Liu L; Trinkner P; Günther S; Bücklein VL; Blumenberg V; Schmidt C; Kunz WG; Von Bergwelt-Baildon M; Theurich S; Subklewe M Haematologica; 2022 Sep; 107(9):2096-2107. PubMed ID: 35172565 [TBL] [Abstract][Full Text] [Related]
10. A major role for CD4 Boulch M; Cazaux M; Cuffel A; Ruggiu M; Allain V; Corre B; Loe-Mie Y; Hosten B; Cisternino S; Auvity S; Thieblemont C; Caillat-Zucman S; Bousso P Cell Rep Med; 2023 Sep; 4(9):101161. PubMed ID: 37595589 [TBL] [Abstract][Full Text] [Related]
11. Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy. Lin MY; Nam E; Shih RM; Shafer A; Bouren A; Ayala Ceja M; Harris C; Khericha M; Vo KH; Kim M; Tseng CH; Chen YY J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38607370 [TBL] [Abstract][Full Text] [Related]
12. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963 [TBL] [Abstract][Full Text] [Related]
13. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Giavridis T; van der Stegen SJC; Eyquem J; Hamieh M; Piersigilli A; Sadelain M Nat Med; 2018 Jun; 24(6):731-738. PubMed ID: 29808005 [TBL] [Abstract][Full Text] [Related]
14. A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting Kumaresan PR; Wurster S; Bavisi K; da Silva TA; Hauser P; Kinnitt J; Albert ND; Bharadwaj U; Neelapu S; Kontoyiannis DP mBio; 2024 Apr; 15(4):e0341323. PubMed ID: 38415653 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy Chen Y; Li R; Shang S; Yang X; Li L; Wang W; Wang Y Front Immunol; 2021; 12():623610. PubMed ID: 34093519 [TBL] [Abstract][Full Text] [Related]
16. Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome. Zheng N; Long Y; Bai Z; Li J; Wang H; Song DD; Liu HL; Shi JH; Zhao S J Transl Med; 2024 Jan; 22(1):58. PubMed ID: 38221609 [TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. Sachdeva M; Duchateau P; Depil S; Poirot L; Valton J J Biol Chem; 2019 Apr; 294(14):5430-5437. PubMed ID: 30804212 [TBL] [Abstract][Full Text] [Related]
18. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy. Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884 [TBL] [Abstract][Full Text] [Related]
19. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication. Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627 [TBL] [Abstract][Full Text] [Related]
20. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia. Li J; Wu Z; Zhao N Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]